Study of Sequential Topoisomerase, Irinotecan/Oxaliplatin - Etoposide /Carboplatin in Extensive Small Cell Lung Cancer (SCLC)

NCT00240097 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Intervention A: Irinotecan; Oxaliplatin; Neulasta
DRUG: Intervention B: Etoposide; Carboplatin; Neulasta

Sponsor

University of Alabama at Birmingham

Collaborators

[object Object]
[object Object]